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Background: Health utility (HU) measures are used as overall measures of quality of life and to determine quality
adjusted life years (QALYs) in economic analyses. We compared baseline values of three HUs including Short Form 6
Dimensions (SF-6D), and Health Utilities Index, Mark II and Mark III (HUI2 and HUI3) and the feeling thermometer
(FT) among type 2 diabetes participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. We
assessed relationships between HU and FT values and patient demographics and clinical variables.
Methods: ACCORD was a randomized clinical trial to test if intensive controls of glucose, blood pressure and lipids can
reduce the risk of major cardiovascular disease (CVD) events in type 2 diabetes patients with high risk of CVD. The
health-related quality of life (HRQOL) sub-study includes 2,053 randomly selected participants. Interclass correlations (ICCs)
and agreement between measures by quartile were used to evaluate relationships between HU’s and the FT. Multivariable
regression models specified relationships between patient variables and each HU and the FT.
Results: The ICCs were 0.245 for FT/SF-6D, 0.313 for HUI3/SF-6D, 0.437 for HUI2/SF-6D, 0.338 for FT/HUI2, 0.337 for FT/
HUI3 and 0.751 for HUI2/HUI3 (P< 0.001 for all). Common classification by quartile was found for the majority (62%) of
values between HUI2 and HUI3, which was significantly (P< 0.001) higher than between other HUs and the FT: SF-6D/
HUI3=40.8%, SF-6D/HUI2= 40.9%, FT/HUI3= 35.0%, FT/HUI2= 34.9%, and FT/SF-6D=31.9%. Common classification was
higher between SF-6D/HUI2 and SF-6D/HUI3 (P< 0.001) than between FT/SF-6D, FT/HUI2, and FT/HUI3. The mean
difference in HU values per patient ranged from −0.024±0.225 for SF-6D/ HUI3 to −0.124± 0.133 for SF-6D/HUI2.
Regression models were significant; clinical and demographic variables explained 6.1% (SF-6D) to 7.7% (HUI3) of the
variance in HUs.
Conclusions: The agreements between the different HUs were poor except for the two HUI measures; therefore HU
values derived different measures may not be comparable. The FT had low agreement with HUs. The relationships
between HUs and demographic and clinical measures demonstrate how severity of diabetes and other clinical and
demographic factors are associated with HUs and FT measures.
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Health utilities (HUs) are summary measures of health-
related quality of life (HRQOL) for health states [1,2]. The
HU scale ranges from 0.00 (dead) to 1.00 (perfect or opti-
mal health) although some instruments allow for negative
states, considered worse than death [1,3,4]. HUs are often
captured indirectly from multiattribute HRQOL surveys in
which responses are converted through scoring algorithms
that are derived from direct measures of HUs. Examples of
indirect HU instruments include the Health Utilities Index,
Mark3 (HUI3) and the Health Utilities Index, Mark2
(HUI2) [3], developed using direct HU measures from the
standard gamble and visual analog scale (VAS) techniques
and the EuroQOL 5-dimensions (EQ-5D) [4], developed
using direct HU measures from time trade-off and VAS
techniques. The Short Form 6-dimensions (SF-6D) is
derived from the Short Form 36 (SF-36), a generic measure
of HRQOL, has also been converted into an HU based
upon standard gamble techniques. The SF-6D expands the
application of SF-36 as an indirect measure of HU [5].
The feeling thermometer (FT) is a visual analog scale
(VAS) from 0 to 100 that is sometimes used as a direct
measure of HU [6-8]. The FT has a role in determining
HUs, but with limitations, such as end-aversion bias (un-
willingness of respondents to select the lowest health
state) and FT results are ordinal values [9-12]. Advan-
tages of the FT as a measure of health status are ease of
administration and simplicity, but its values require con-
version, based upon classical direct HU measures
[12,13].
Previously, researchers have identified differences in
HUs derived from the SF-6D with those of the EQ-5D,
VAS, or the HUI [14,15]. For example, SF-6D values
have been shown to be higher than HUI values [14,16] in
some studies and lower in another [17]. Since HUs are
used to calculate quality adjusted life years (QALYs),
these differences may be important in cost effectiveness
analyses (CEA) of diabetes treatments as well as other
conditions [18,19]. Disparate CEA results may be asso-
ciated with method of calculating HUs, and its impact
on QALYs [20]. Pickard et al. calculated HUs from 2
published studies using 10 different methods, based
upon SF-36 and SF-12 data [20]. Based on an incremen-
tal cost difference of $2000 between treatments, the in-
cremental CEA ratios ranged from $30,769 to $63,492
per QALY for an asthma study and $27,972 to $72,727
per QALY for a stroke treatment study [20]. Thus, the
CEA decision could be dependent upon which method
was used to calculate HUs. Previous research has shown
that CEA results are sensitive to HU values. For example
in a CEA modeling study of a diabetes prevention pro-
gram, decreasing the improvement in HU values by 0.04
among participants, significantly increased the cost per
QALY ratio by up to $10,000 [21].Patient characteristics and disease severity should be
associated with HUs. If they are not, the HU technique
may be insensitive to important differences in the disease’s
severity. Thus, the assessment of relationships between
HUs and disease severity measures helps establish the sen-
sitivity of a particular HU measure. Relationships between
diabetes severity and HUI values have been found, with
greater levels of complications associated with lower HUs
[22-24]. The SF-6D and VAS have been shown to discrim-
inate severity of diabetes [25] and obesity [26,27]. Similar
findings were found in a study among patients with coron-
ary artery disease, which indicated that SF-6D and the
HUI discriminate groups defined by gender and symp-
toms, as well as responsiveness to changes in angina pain
over time [14].
Our first objective was to compare HUs calculated
using standardized scoring algorithms, the HUI2, HUI3
and the SF-6D and the FT values among participants en-
rolled in the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial. Our second objective was to
assess relationships between each HU and demographic
characteristics, clinical measures, diabetic complications,
and comorbidities.
Patients and methods
ACCORD was designed to compare the effect of inten-
sive versus less intensive control of glucose, blood pres-
sure and lipids on CVD event rates among participants
with type 2 diabetes who are at risk for cardiovascular
events. This randomized, controlled clinical trial was con-
ducted over 8 years (estimated mean patient follow-up of
5.6 years) among 10,251 participants at 77 study sites in
the United States and Canada (www.accordtrial.org) [28].
The intensive glucose control arm of the study was discon-
tinued in February 2008 due to increased mortality com-
pared to less intensive control and the blood pressure and
lipid control arms were completed in 2009 [29].
CEA was incorporated into ACCORD as a sub-study
[30]. All sites obtained institutional review board ap-
proval for ACCORD and the CEA sub-study. Partici-
pants were randomly selected for participation in the
CEA sub-study and completed informed consent. There
were 4311 participants enrolled in the CEA sub-study
and, nested within this sample, 2053 participants com-
pleted HRQOL instruments at baseline and 12, 36, and
48 months. For this cross-sectional study we examined
baseline results from the SF-36, Version 2 (RAND
Corporation, Santa Monica, CA), the Health Utilities
Index (Health Utilities Inc., Dundas, Ontario, Canada),
and the FT. ACCORD inclusion/exclusion criteria are
described elsewhere [31]. All HRQOL sub-study partici-
pants who completed baseline measures of all three
instruments were included, but forms with missing data
were excluded from the analyses.
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The SF-36 was converted into the SF-6D HU score, using
techniques previously described [32]. The HUI was scored
according to both the HUI2 and the HUI3 algorithms,
resulting in two HU scores [3]. The FT represents how the
patient feels on a 0 to 100 scale. We converted the FT
values to 0.00 to 1.00 (dividing by 100) because values
range from below 0.00 to 1.00 for the other instruments in
the study, Demographics, physiologic and laboratory mea-
sures, complications, and comorbidities were obtained
from baseline case report forms. All data have been edited
according to data capture and verification procedures
established for the ACCORD trial. For all statistical ana-
lyses, a two-sided alpha was set at 0.05.
For our first objective, we calculated pair-wise intra-
class correlation coefficients (ICCs) using one-way ran-
dom models to determine level of agreement between
HU instrument scores as well as FT values [33]. We also
divided the scores into quartiles, and determined
whether values from each HU or the FT, fell within the
same quartiles. We analyzed the level of agreement be-
tween the pairs of instruments using chi square tests.
We also calculated the mean differences per patient (and
95% confidence intervals) between pairs of instruments
to determine the extent of variation between the HUs.
For the second objective, we developed multiple re-
gression models with HUs or FT values as dependent
variables and demographics, clinical measures, and dia-
betes complications as independent variables. Categorical
variables were entered into the model as indicator vari-
ables (for example, presence of characteristics = 1, ab-
sence = 0). We used a stepwise, forward selection process
with p< 0.5 and report the variables that were significant
contributors to the model at p< 0.05 All data computa-
tion and analyses were performed using SAS Software,
V9.1 (SAS Institute). We tested normality of the distribu-
tions of HUs and FT using Kolmogorov-Smirnov tests
and assessed Goodness of Fit for the models based on
the significant F values.
Results
After removing surveys with missing responses, the final
sample sizes included in the study were n= 1951 (95.0%)
for SF-6D and n= 2035 (99.1%) for HUI2, HUI3, and FT.
For analyses comparing correlation and agreement among
HU measures, we included only observations with all four
measures. For regression analyses, we used any observa-
tion with that particular HU or FT score, regardless of the
completeness of the other HU scores.
Table 1 displays the alignment of demographic variables
for this sub-study sample and the overall ACCORD trial.
There are no significant differences. The mean± standard
deviation (median) were: SF-6D=0.684± 0.085 (0.696),
HUI2= 0.806±0.156 (0.849), HUI3= 0.707±0.258 (0.778),and FT=0.748±0.168 (0.78). The values were normally
distributed (Kolmogorov-Smirnov tests).
Figure 1 displays the cumulative distribution plots of all
HU instruments and the FT. The SF-6D scores encom-
passed a narrower range than the other instruments. The
middle 2 quartiles (26% to 75%) for SF-6D range from 0.62
and 0.74, versus 0.65 to 0.85 for FT, 0.76 to 0.92 for HUI2,
and 0.57 to 0.92 for HUI3. This is demonstrated by the
steepness of the slope of the middle of the distribution
curve for the SF-6D (Figure 1). Another difference is that
participants’ responses to the FT tended toward specific
values listed on the scale, increments of 0.05 and 0.10. This
is shown by the stepped appearance of the distribution plot
for the FT. We note that 1044 (51.3%) of FT scores fell on
a multiple of 0.10, and another 714 (35.1%) fell on other
multiples of 0.05, for a combined total of 1758 (86.4%).
Thus, the FT scale differentiated most scores by 0.05 point
intervals, whereas calculated scores from other instru-
ments can be any possible value within the scoring range.
ICCs between instruments represent strong agreement
between HUI2 and HUI3 (0.733, 95% confidence interval
(CI) 0.732-0.734). However there was poor agreement
between FT and SF-6D (0.245 CI: 0.241-0248). There
was only fair agreement between HUI3 and SF-6D (0.313
CI: 0.266-0.358), HUI2 and SF-6D (0.437 CI: 0.436-
0.438), FT and HUI2 (0.337 CI: 0.332-0.342), and FT and
HUI3 (0.337 CI: 0.317-0.353). All ICCs were statistically
significant (p< 0.01).
Figure 2 displays comparisons between each pair of
instruments by quartile. The greatest disparities between
instruments, with participant scores in highest quartile of
one instrument but the lowest quartile of another, were be-
tween the FT versus all other instruments. Similarly more
of the FT scores were 1 or 2 quartiles different from HU
values. The significant differences in percent agreement be-
tween pairs of HU instruments and the FT are listed. HUI2
and HUI3 were in agreement significantly more than all
other pairs. The SF-6D/HUI3 and SF-6D/HUI2 were in
agreement significantly more than the any of the FT pairs.
The mean differences (95% CIs) were: SF-6D/HUI2=
−0.124 (−0.386 to 0.137). SF-6D/HUI3=−0.024 (−0.466 to
0.417), SF-6D/FT=−0.065 (−0.386 to 0.256), FT/HUI2=
−0.058 (−0.424 to 0.308), FT/HUI3 =0.041 (−0.450 to
0.533), and HUI2/HUI3=0.10 (−0.205 to 0.404). Similar to
the disagreements between quartiles and ICCs, the confi-
dence intervals reflect large differences between scores for
some patients.
The results of the adjusted multivariable regression mod-
els for each instrument are shown in Tables 2 and 3. The
models were statistically significant (p< 0.001) and
explained 6.1% to 7.8% of the variances. The variables com-
mon to all models were female gender, secondary CVD, dia-
betes duration, and current smoking, which were associated
with significantly lower values. Education, total cholesterol,
Table 1 Demographic and physiologic variables of all








Mean Age, Yrs 62.2 ±6.8 62.2 ±6.7
Median Age, Yrs 62 62
% Female 38.6 39.6
% White 64.8 65.9
% Black 19.3 19.4
% Hispanic 7.2 6.8




% Less than High School 14.8 13.9
% High School Graduate 26.4 26




Cigarette Smoker . .
% Never 41.8 41.2
% Former 44.2 45.6




Mean Duration of Diabetes, Yrs 10.8 ± 7.8 11.1 ± 7.8
Median Duration of Diabetes, Yrs 10 10
Mean glycated hemoglobin
(HbA1c), %
8.3 ± 1.1 8.3 ±1.1
Median HbA1c, % 8.1 8.1
Mean Fasting Plasma
Glucose, mg/%
175.3 ±56.2 177.1 ±57.6
Mean Serum Creatinine, mg/ml 0.9 ±0.2 0.9 ±0.2
Mean Glomerular Filtration Rate,
ml/min
91.1 ±27.1 91.7 ±31.3
Mean Weight, lbs 206.2 ±41.1 207.5 ±41.7
Body Mass Index, kg/m2 32.2 ±5.5 32.4 ±5.5
Waist Circumference, inches 42 ±5.5 42.1 ±5.5
Mean Systolic Blood Pressure
(mm/HG)
136.4 ±17.1 136.2 ±17.1
Mean Diastolic Blood Pressure
(mm/HG)
74.9 ±10.7 74.5 ±10.9
% On Any Hypertension
Medications
85.4 85.5
% On Any Angiotensin-receptor
converting enzyme Inhibitors
53 52
% on Beta Blockers 29.3 30.3
Mean Low Density Lipoprotein
(LDL) (mg/dl)
104.9 ±33.9 104.3 ±34.0
High Density Lipoprotein
(HDL) (mg/dl)
41.9 ±11.6 42.1 ±11.7
HDL among Females (mg/dl) 47 ±12.6 47.3 ±12.6
HDL among Males (mg/dl) 38.6 ±9.6 38.7 ±9.7
Table 1 Demographic and physiologic variables of all
ACCORD participants versus health-related quality of life
(HRQOL) sample (Continued)
Total Cholesterol (mg/dl) 183.3 ±41.9 182.8 ±41.3
Non-HDL Cholesterol (mg/dl) 141.4 ±41.4 140.7 ±40.9
% with High Triglyceride 23.3 23.3
Median Triglycerides (mg/dl) 155 156
% On Statins 62.1 63.5
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cantly higher values in all models except the FT. It is inter-
esting that greater age was associated with slightly higher
values for all models except HUI3. It could be that older
patients had lower values of other predictors that were sig-
nificant negatively and that the age variable adjusted for
those differences. We note that for each model where age
was a predictor, it was entered at a higher step (data avail-
able upon request). Other researchers have found positive
relationships between age and HUs [34]. Aspirin consump-
tion was associated with significantly higher values for
HUI2 and FT. Hispanic race was associated significantly
lower values for SF-6D and HUI3. African American race
was associated with significantly higher FT scores. Increased
body mass index (HUI2 and HUI3) or waist circumference
(FT and SF-6D) was associated with significantly lower
values.Discussion
There were significant differences between the 3 meth-
ods of measuring HUs and the FT.Figure 1 Health utility and feeling thermometer scores by
measurement technique, with cumulative distributions.
Figure 2 Within quartile agreement between instruments by
quartile. HUI =Health Utilities Index, FT = Feeling Thermometer,
SF-6D= Short Form-6 Dimensions, Disagreement = top quartile of
one score, lowest quartile of other score, Significantly higher %
agreement: HUI2/HUI3 versus all others (P< 0.001):, SF-6D/HUI3
versus FT/HUI3, FT/HUI2, FT/SF-6D (all P< 0.001), SF-6D/HUI2 versus
FT/HUI3 (P= 0.008), FT/HUI2 (P= 0.003), FT/SF-6D (P< 0.001), FT/HUI3
versus FT/SF-6D (P= 0.04).
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We note that each sample of patients are dissimilar
and thus are not directly comparable to our results,
however we did identify similarities to previous stud-
ies. The range of mean HU values across the instru-
ments (0.684 to 0.818) in our study were similar to
those reported in Action in Diabetes and Vascular
Disease study (ADVANCE) which used the SF-6D
and the EQ5D (0.678 to 0.801) [35]. The mean FT
value in our study (0.748) is similar to the mean
value reported among participants of United King-
dom Progressive Diabetes Study (0.74) [36] and
among patients with obesity (0.751) [27]. However,
our mean FT value was higher than the value
reported in the Cost of Diabetes in Europe -Type 2
(CODE-2) (0.628, converted from 62.8 to have simi-
lar decimal places to our results) [37] and the FT
value found by Matza, et al. among patients with
diabetes (0.623) [38]. The differences may reflect
study instrument administration techniques as well
as differences in study samples. In a study designed
to determine the impact of hypothetical diabetes
medication outcomes, the patients’ FT scores from
diabetes were lower than ACCORD participants, who
had higher rates of hypertension (85.4% vs. 37.2%),
while body mass index (BMI) was similar (32.2 vs.
31.3) [38]. A study using time-tradeoff measuresfound a mean HU of 0.76 for conventional glucose
control [18], which is similar the FT HU obtained
from ACCORD participants at baseline.
Measurement characteristics: comparisons between
instruments
The cumulative distributions (Figure 1) help eluci-
date differences between the methods. The FT scores
were concentrated at the interval values listed on the
instrument, for example, multiples of 0.05 or 0.10.
This finding may suggest lower sensitivity to changes
in HRQOL smaller than 0.05, which is smaller than
what has been suggested as a clinically important dif-
ference in HU (0.03) [39]. The limitations of the FT
when compared to HU measures have been previ-
ously described [13,40].
HUs obtained from the SF-6D varied by the smallest
range among the middle 50% of the patients (from quar-
tiles >25% to <76%), the difference was only 0.12 points
for the SF-6D versus 0.21 for FT, 0.18 for HUI2, and
0.35 for HUI3. The finding suggests that the scoring al-
gorithm for the SF-6D may be less sensitive to differ-
ences in HUs among participants whose scores are
within this range. A narrower range of scores for the SF-
6D has been previously documented when compared to
the EQ-5D, and is considered a potential limitation of
the SF-6D [41,42]. The narrow scoring range of the SF-
6D was also demonstrated among rheumatoid arthritis
participants when compared with HUI3 and EQ-5D [43]
and among participants in an implantable defibrillator
study when compared with the HUI3 [17]. The HUI2
scoring range was also narrow among the middle 50% of
patients (Figure 1), as was previously shown among
rheumatoid arthritis patients [43]. The HUI3 cumulative
distribution plot is the most gradual across the mid-
range scores, suggesting more differentiation between
participants within the middle quartiles.
We note several differences between the HUI 2 and
HUI3. The HUI3 includes scales for vision, hearing, and
speech versus a sensation domain for the HUI2; has sep-
arate domains for dexterity and ambulation versus mo-
bility for HUI2; and uses different questions for emotion
and pain. Therefore the domain scores are not directly
comparable. Only the domain of cognition uses the same
questions, but cognition is scored differently between the
2 instruments (6 levels in HUI3 compared to 4 levels in
HUI2) Furthermore, the domain scores are then entered
into different scoring algorithms for the HUI2 and HUI3,
resulting in different values. We note that since the
HUI3 differentiates patients more broadly within the
middle quartiles, it may be a better method for scoring
the HUI in the ACCORD population. The ACCORD
CEA sub-study planning committee selected the HUI3 a
priori [30].
Table 2 Multivariable regression results by instrument *
Variable SF-6D Health Utilities Index 3
Score











valueEstimate Estimate Estimate Estimate
0-Intercept 0.756 <.0001 1.038 <.0001 0.907 <.0001 1.012 <.0001
Aspirin . . . . 0.014 0.041 0.015 0.041
Body mass
index
. . −0.006 <.0001 −0.004 <.0001 −0.002 0.062




−0.002 <.0001 . . . . −0.003 0.010
Age 0.001 0.043 . . 0.001 0.007 0.002 0.001
Black . . . . . . 0.060 <.0001
Total
cholesterol




−0.001 0.002 −0.002 0.005 −0.001 0.001 −0.001 0.011
Educational
level
0.005 0.006 0.023 <.0001 0.014 <.0001 . .
Female −0.024 <.0001 −0.040 0.001 −0.030 <.0001 −0.043 <.0001
Glycated
hemoglobin
. . . . . . −0.014 <.0001
Low density
lipoprotein




−0.013 0.001 −0.069 <.0001 −0.032 <.0001 −0.018 0.021
Smoking −0.009 0.003 −0.040 <.0001 −0.027 <.0001 −0.019 0.001
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ception of the expected higher value between the HUI2 and
HUI3 scoring algorithms, provide a summary statistic
showing poor or fair agreement between the instruments.
Fair agreement between SF-6D and HUI3 was found among
patients in an implantable cardiac defibrillator trial (ICC=
0.45) [17] and a percutaneous coronary intervention trial
(ICC=0.40) [14]. Our results by quartile describe these dis-
crepancies more specifically. Comparing the FT and HUI2,
6.1% (n=123) participants would be measured as being in
the highest quartile by one instrument, while scoring in the
lowest quartile of the other (Figure 2). Furthermore, an add-
itional 19.2% (n=383) of comparisons between the FT and
the HUI2 differ by two quartiles.
The mean (± standard deviations) differences per partici-
pant showed similar results, with average differences from
0.100 (HUI2/HUI3) to −0.122 (SF-6D/HUI2) and 95% con-
fidence intervals as great as −0465 to 0.417 (SF-6D/HUI2).
These large discrepancies indicate that the choice of HUinstrument could impact results of the overall CEA. Specif-
ically, one instrument might show increased HU over time
while another shows a negative or no impact in the same
participant. Such discrepancies between HUs have been
identified previously among a primary care population in
East Asia [44] and among rheumatoid arthritis patients in
British Columbia [43]. A longitudinal analysis is needed to
determine the full impact of these discrepancies in regard
to sensitivity to changes in physiologic diabetes measure-
ments (e.g. glycated hemoglobin or cardiovascular
complications).
Relationships between HUs and clinical and demographic
variables
In multivariable analyses, we identified significant relation-
ships between HUs and FT values. Comorbidities negatively
associated with HUs were presence of CVD, current smok-
ing, and obesity measured by BMI or waist circumference.
Either waist circumference or BMI were significant for all
Table 3 Values for Significant Categorical Variables in Multivariable Regression
Variable SF-6D HUI3 Score HUI2 Score Feeling Thermometer
Aspirin No 0.660 0.648 0.774 0.750
Yes 0.667 0.667 0.788 0.765
NonWhite No 0.666 0.678 0.789 0.784
Yes 0.661 0.636 0.773 0.731
Black No 0.664 0.634 0.779 0.720
Yes 0.663 0.681 0.783 0.796
Education Less than High School 0.655 0.616 0.759 0.757
High School Graduate 0.662 0.662 0.781 0.757
Some College 0.663 0.641 0.776 0.755
College Graduate 0.673 0.709 0.809 0.763
Female No 0.673 0.677 0.793 0.776
Yes 0.654 0.637 0.769 0.740
Secondary cardiovascular disease No 0.671 0.689 0.795 0.766
Yes 0.656 0.625 0.767 0.750
Smoking No 0.672 0.692 0.805 0.776
Previous 0.669 0.686 0.795 0.768
Current 0.650 0.594 0.743 0.729
Hispanic No 0.675 0.668 0.782 0.743
Yes 0.652 0.646 0.780 0.773
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BMI was significant it may have addressed the variance in
HUs associated with waist circumference and vice versa.
Previously, in a study of the impact of long-term diabetic
complications on HRQOL, BMI was a significant predictor
in all regression analyses of SF-36 domains with the excep-
tion of mental health [45]. Similarly, in CODE-2, obesity
was a significant predictor of VAS scores [37]. Relationships
between VAS and obesity have also been shown among
patients with obesity without a diagnosis of diabetes [46].
History of CVD was significantly associated with lower HU
and FT values. Significant relationships between HU and
CVD among patients with diabetes have been shown in
other studies [35-37,45].
Among physiologic measures, total cholesterol and low-
density lipoprotein were significantly associated with lower
values for all HU instruments, but not for the FT. Glycated
hemoglobin was only associated with FT values. None of
the renal function measures (serum creatinine, micro- and
macro-albuminuria) were significant in any models. Regard-
ing use of blood pressure, lipid, and glycemic medications;
none were significant in multivariable models. Our models
were similar to a study of diabetes-related complications,
which used the EQ-5D in 1143 Canadian participants [34].
Specifically, the researchers reported significant relation-
ships between HU and duration of diabetes (negative), age
and male gender (both positive), and CVD complications
(myocardial infarction and stroke, negative).Recently a simulation study was conducted to demon-
strate the impact of complications on life expectancy
among patients with Type 2 diabetes using data from the
Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) study [47]. The simulation study showed that an
HU less than 1.00 at baseline was associated with
increased all-cause mortality and lower quality adjusted
life expectancy [47]. Occurrences of diabetic complica-
tions were associated with a mean decrease of 0.045 HU
(95% CI =−0.073 to −0.017), as measured by the EQ-5D
[47]. The greatest impact on HU was stroke (−0.165 HU.
95% CI =−0.246 to −0.0840). Similarly, in our multivari-
able models we found secondary CVD to be associated
with significantly lower HU at baseline (Tables 2 and 3).
The association varied by type of measure, SF- 6D
(−0.015), HUI3 (−0.064), and HUI2 (−0.028).
We note that clinical and demographic factors associated
with HU are similar to results of an observational trial of
predictors of hypertension management [48]; in which per-
sons with diabetes, obesity and Hispanic ethnicity were
found to have decreased blood pressure control. The study
found the lowest percent of patients with controlled blood
pressure control (23%) among diabetic persons with obesity
[48].
Adequate goal attainment of CVD risk factors continues
to be illusive among persons with Type 2 diabetes. In a
study of the data from National Health and Nutritional
Examination Survey from 1999 to 2008, goal attainment
Raisch et al. Cardiovascular Diabetology 2012, 11:35 Page 8 of 9
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from 29.7% to 54.4%, but control of hypertension did not
significantly improve (47.6% to 55.1%; P=0.1333) even
though significantly more patients were receiving antihyper-
tensive medications (35.4% to 58.9%; P< 0.0001) [49].
Prevalence of hypertension was not significantly increased
from 1999 to 2008 (66.6% to 74.2%; P=0.3724) [49].
Another concern is under-diagnosis of diabetes among
CVD patients. Researchers reviewed health records of all
Danish myocardial infarction (MI) patients who were not
previously diagnosed with diabetes to identify the initiation
of glucose lowering medications within 1 year after dis-
charge [50]. The rates increased from 19.6 to 27.6 per 1000
person year from 1997 to 2001, at which time the rates lev-
eled off through 2005 [50]. These rates were much lower
than expected, since other researchers had shown higher
rates of abnormal glucose tolerance among MI patients.
However a recent population study of screening for diabetes
and CVD found no difference in HU among screened ver-
sus non-screened populations [51].
A limitation of the study is that ACCORD participants
are a select group (i.e. mean age> 62, type II diabetics who
met study inclusion criteria and were at risk for CVD); thus,
our results are not generalizable to all other individuals with
type 2 diabetes. Further research would be needed to make
comparisons to other patient groups with type 2 diabetes.
This analysis is limited to baseline measures only; our
results do not indicate how values may be influenced by
changes in diabetes severity or the study interventions over
time.
We identified significant differences in HU values
obtained from the SF6D, HUI2 and HUI3. Since differences
in HU values could impact CEA results, the type of patient
preference measure used is an important consideration in
designing and interpreting CEAs. Although we found statis-
tically significant relationships between HUs and demo-
graphic and clinical variables, the variances explained by the
models were relatively small (6.1% to 7.7%).
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